✦ LIBER ✦

Pathologic Complete Response May Not Represent the Optimal Surrogate for Survival After Preoperative Therapy for Esophageal Cancer

✍ Scribed by Blackstock, A. William ;Aklilu, Mabea ;Lovato, James ;Farmer, Michael R. ;Mishra, Girish ;Melin, Susan A. ;Oaks, Timothy ;Geisinger, Kim ;Levine, Edward A.

Book ID: 111638990
Publisher: Springer
Year: 2006
Tongue: English
Weight: 80 KB
Volume: 37
Category: Article
ISSN: 1537-3649
DOI: 10.1385/ijgc:37:1:7

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Complete Metabolic Response Is Not Unifo

Complete Metabolic Response Is Not Uniformly Predictive of Complete Pathologic Response After Induction Therapy for Esophageal Cancer

✍ Stiles, Brendon M.; Salzler, Gregory; Jorgensen, Anna; Nasar, Abu; Paul, Subroto 📂 Article 📅 2013 🏛 Elsevier Science 🌐 English ⚖ 254 KB

Survival outcomes of resected patients w

Survival outcomes of resected patients who demonstrate a pathologic complete response after neoadjuvant chemoradiation therapy for locally advanced esophageal cancer

✍ Z. T. Hammoud; K. A. Kesler; M. K. Ferguson; R. J. Battafarrano; A. Bhogaraju; N 📂 Article 📅 2006 🏛 John Wiley and Sons 🌐 English ⚖ 84 KB

Pathological complete response and survi

Pathological complete response and survival according to the level of HER-2 amplification after trastuzumab-based neoadjuvant therapy for breast cancer

✍ Guiu, S; Gauthier, M; Coudert, B; Bonnetain, F; Favier, L; Ladoire, S; Tixier, H 📂 Article 📅 2010 🏛 Nature Publishing Group 🌐 English ⚖ 413 KB

Pathological complete response and survi

Pathological complete response and survival according to the level of HER-2 amplification after trastuzumab-based neoadjuvant therapy for breast cancer

✍ Ross, J.S. 📂 Article 📅 2011 🏛 Elsevier Science 🌐 English ⚖ 53 KB

Marimastat may not improve survival over

Marimastat may not improve survival over placebo following induction therapy for small-cell lung cancer: Abstracted from: Shepherd F, Giaccone G, Seymour L et al. Prospective, randomized, double-blind, placebo-controlled trial of marimastat after response to first-line chemotherapy in patients with small-cell lung cancer: a trial of the National Cancer Institute of Canada-Clinical Trials Group and the European Organization for Research and Treatment of Cancer. J Clin Oncol 2002; 20(22): 4434–39.

✍ B Coudert 📂 Article 📅 2003 🏛 Elsevier Science 🌐 English ⚖ 71 KB